secwatch.observer — SEC 8-K summary
======================================

Issuer:     CORCEPT THERAPEUTICS INC (CORT)
CIK:        0001088856
Form:       8-K
Filed at:   2023-11-01T23:59:59+00:00
Accession:  0001628280-23-035979
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Corcept Q3 revenue $123.6M (+22% YoY); raises FY 2023 guidance to $470-$480M
----------------------------------------------------------------------------

- Revenue $123.6M (+22% YoY); net income $31.4M ($0.28 diluted EPS) vs $34.6M ($0.30) in Q3 2022.
- FY 2023 revenue guidance raised to $470-$480M from previous $455-$470M.
- Cash and investments $414.8M at Sept 30, up from $363.3M end of prior quarter.
- GRACE Phase 3 enrollment complete; NDA for relacorilant in Cushing's expected Q2 2024.
- Key 2024 trial readouts: GRADIENT (mid-2024), ROSELLA, DAZALS (year-end 2024), CATALYST prevalence (Q1 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/0001628280-23-035979-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1088856/000162828023035979/cort-20231101.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-035979

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer